Mortimer Mamelak
Overview
Explore the profile of Mortimer Mamelak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mamelak M
Curr Neuropharmacol
. 2024 Aug;
23(1):75-84.
PMID: 39150032
Many features of major depressive disorder are mirrored in rodent models of psychological stress. These models have been used to examine the relationship between the activation of the hypothalamic- pituitary...
2.
Mamelak M
J Alzheimers Dis
. 2023 Aug;
99(s1):S109-S118.
PMID: 37599534
The deterioration of the brain's microvasculature, particularly in the hippocampus, appears to be a very early event in the development of Alzheimer's disease (AD), preceding even the deposition of amyloid-β....
3.
Mamelak M
Curr Mol Pharmacol
. 2022 Nov;
16(5):564-579.
PMID: 36330625
Sodiun Oxybate (SO) has a number of attributes that may mitigate the metabolic stress on the substantia nigra pars compacta (SNpc) dopaminergic (DA) neurons in Parkinson's disease (PD). These neurons...
4.
Yung J, Yeung L, Ivovic A, Tan Y, Jentz E, Batchuluun B, et al.
Cells
. 2022 Feb;
11(3).
PMID: 35159354
Oxidative stress caused by the exposure of pancreatic ß-cells to high levels of fatty acids impairs insulin secretion. This lipotoxicity is thought to play an important role in ß-cell failure...
5.
Kish S, OLeary G, Mamelak M, McCluskey T, Warsh J, Shapiro C, et al.
Hum Psychopharmacol
. 2021 Apr;
36(5):e2791.
PMID: 33899252
Objective: To establish in an exploratory neuroimaging study whether γ-hydroxybutyrate (sodium oxybate [SO]), a sedative, anti-narcoleptic drug with abuse potential, transiently inhibits striatal dopamine release in the human. Methods: Ten...
6.
Mamelak M
Curr Neuropharmacol
. 2021 Apr;
20(2):272-291.
PMID: 33827411
Sodium oxybate (SO) has been in use for many decades to treat narcolepsy with cataplexy. It functions as a weak GABAB agonist but also as an energy source for the...
7.
Mamelak M
Curr Neuropharmacol
. 2020 Jan;
18(8):754-768.
PMID: 31934840
The cannabinoids, Δ9 tetrahydrocannabinol and its analogue, nabilone, have been found to reliably attenuate the intensity and frequency of post-traumatic nightmares. This essay examines how a traumatic event is captured...
8.
Mamelak M
Neurol Ther
. 2018 Jan;
7(1):5-11.
PMID: 29368093
The high energy demands of the substantia nigra pars compacta dopaminergic (DASNc) neurons render these neurons vulnerable to degeneration. These energy demands are a function of their long and extensively...
9.
Bogan R, Black J, Swick T, Mamelak M, Kovacevic-Ristanovic R, Villa K, et al.
Neurol Ther
. 2017 Jul;
6(2):237-245.
PMID: 28707076
Introduction: Narcolepsy patients report lower health-related quality of life (HRQoL) than the general population, as measured by the Short Form-36 Health Survey (SF-36). This analysis evaluated whether changes in SF-36...
10.
Mamelak M
Neurosci Biobehav Rev
. 2017 Feb;
75:297-313.
PMID: 28193453
The high energy demands of the poorly myelinated long axon hippocampal and cortical neurons render these neurons selectively vulnerable to degeneration in Alzheimer's disease. However, pathology engages all of the...